Revised response criteria for malignant lymphoma

Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl; International Harmonization Project on Lymphoma

doi:http://dx.doi.org/10.1200/JCO.2006.09.2403

Revised response criteria for malignant lymphoma

Bruce D Cheson, Beate Pfistner, Malik E Juweid, Randy D Gascoyne, Lena Specht, Sandra J Horning, Bertrand Coiffier, Richard I Fisher, Anton Hagenbeek, Emanuele Zucca, Steven T Rosen, Sigrid Stroobants, T Andrew Lister, Richard T Hoppe, Martin Dreyling, Kensei Tobinai, Julie M Vose, Joseph M Connors, Massimo Federico, Volker DiehlInternational Harmonization Project on Lymphoma

3353 Citations (Scopus)

Abstract

PURPOSE: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. METHODS: The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations. RESULTS: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. CONCLUSION: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.

Original language	English
Journal	Journal of Clinical Oncology
Volume	25
Issue number	5
Pages (from-to)	579-86
Number of pages	8
ISSN	0732-183X
DOIs	https://doi.org/10.1200/JCO.2006.09.2403
Publication status	Published - 10 Feb 2007

Access to Document

http://dx.doi.org/10.1200/JCO.2006.09.2403

Cite this

Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., Rosen, S. T., Stroobants, S., Lister, T. A., Hoppe, R. T., Dreyling, M., Tobinai, K., Vose, J. M., Connors, J. M., Federico, M., ... International Harmonization Project on Lymphoma (2007). Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25(5), 579-86. https://doi.org/10.1200/JCO.2006.09.2403

Cheson, BD, Pfistner, B, Juweid, ME, Gascoyne, RD, Specht, L, Horning, SJ, Coiffier, B, Fisher, RI, Hagenbeek, A, Zucca, E, Rosen, ST, Stroobants, S, Lister, TA, Hoppe, RT, Dreyling, M, Tobinai, K, Vose, JM, Connors, JM, Federico, M, Diehl, V & International Harmonization Project on Lymphoma 2007, 'Revised response criteria for malignant lymphoma', Journal of Clinical Oncology, vol. 25, no. 5, pp. 579-86. https://doi.org/10.1200/JCO.2006.09.2403

@article{d0552c304c7d11df928f000ea68e967b,

title = "Revised response criteria for malignant lymphoma",

abstract = "PURPOSE: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. METHODS: The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations. RESULTS: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. CONCLUSION: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.",

author = "Cheson, {Bruce D} and Beate Pfistner and Juweid, {Malik E} and Gascoyne, {Randy D} and Lena Specht and Horning, {Sandra J} and Bertrand Coiffier and Fisher, {Richard I} and Anton Hagenbeek and Emanuele Zucca and Rosen, {Steven T} and Sigrid Stroobants and Lister, {T Andrew} and Hoppe, {Richard T} and Martin Dreyling and Kensei Tobinai and Vose, {Julie M} and Connors, {Joseph M} and Massimo Federico and Volker Diehl and Lena Specht",

note = "Keywords: Clinical Trials as Topic; Endpoint Determination; Flow Cytometry; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Image Interpretation, Computer-Assisted; Immunohistochemistry; Lymphoma, Non-Hodgkin; Positron-Emission Tomography; Radiopharmaceuticals; Survival Analysis; Terminology as Topic; Time Factors; Tomography, X-Ray Computed; Treatment Outcome",

year = "2007",

month = feb,

day = "10",

doi = "http://dx.doi.org/10.1200/JCO.2006.09.2403",

language = "English",

volume = "25",

pages = "579--86",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "5",

}

TY - JOUR

T1 - Revised response criteria for malignant lymphoma

AU - Cheson, Bruce D

AU - Pfistner, Beate

AU - Juweid, Malik E

AU - Gascoyne, Randy D

AU - Specht, Lena

AU - Horning, Sandra J

AU - Coiffier, Bertrand

AU - Fisher, Richard I

AU - Hagenbeek, Anton

AU - Zucca, Emanuele

AU - Rosen, Steven T

AU - Stroobants, Sigrid

AU - Lister, T Andrew

AU - Hoppe, Richard T

AU - Dreyling, Martin

AU - Tobinai, Kensei

AU - Vose, Julie M

AU - Connors, Joseph M

AU - Federico, Massimo

AU - Diehl, Volker

AU - International Harmonization Project on Lymphoma

N1 - Keywords: Clinical Trials as Topic; Endpoint Determination; Flow Cytometry; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Image Interpretation, Computer-Assisted; Immunohistochemistry; Lymphoma, Non-Hodgkin; Positron-Emission Tomography; Radiopharmaceuticals; Survival Analysis; Terminology as Topic; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

PY - 2007/2/10

Y1 - 2007/2/10

N2 - PURPOSE: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. METHODS: The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations. RESULTS: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. CONCLUSION: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.

AB - PURPOSE: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. METHODS: The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations. RESULTS: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. CONCLUSION: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.

U2 - http://dx.doi.org/10.1200/JCO.2006.09.2403

DO - http://dx.doi.org/10.1200/JCO.2006.09.2403

M3 - Journal article

SN - 0732-183X

VL - 25

SP - 579

EP - 586

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 5

ER -

Revised response criteria for malignant lymphoma

Abstract

Access to Document

Fingerprint

Cite this